CML had been initially treated with imatinib for 4 years with good response (MMR, ≤ 0.1% BCR::ABL1 on the BCR::ABL1 International Scale) and then changed to nilotinib 200 mg twice daily for 7 years with deep molecular response (MR4 ≤ 0.01% BCR::ABL1, MR4,5 ≤ 0.0032% BCR::ABL1 on the BCR::ABL1 International Scale), which was discontinued and replaced by bosutinib due to acute MI. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.